IRIS
SVICHER, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43.857
AS - Asia 7.788
EU - Europa 6.324
SA - Sud America 1.135
AF - Africa 151
OC - Oceania 107
Continente sconosciuto - Info sul continente non disponibili 16
Totale 59.378
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 43.596
SG - Singapore 4.056
CN - Cina 1.308
IT - Italia 1.278
BR - Brasile 930
DE - Germania 816
RU - Federazione Russa 815
HK - Hong Kong 663
VN - Vietnam 563
UA - Ucraina 511
FR - Francia 492
SE - Svezia 452
IE - Irlanda 451
PL - Polonia 394
FI - Finlandia 374
GB - Regno Unito 318
KR - Corea 242
BD - Bangladesh 233
JP - Giappone 227
CA - Canada 143
IN - India 128
AU - Australia 100
ES - Italia 93
NL - Olanda 91
AR - Argentina 72
MX - Messico 63
ID - Indonesia 60
TR - Turchia 52
BE - Belgio 51
AT - Austria 47
CZ - Repubblica Ceca 47
IQ - Iraq 44
ZA - Sudafrica 42
CO - Colombia 35
EC - Ecuador 33
PH - Filippine 30
PK - Pakistan 20
MA - Marocco 19
CL - Cile 18
JM - Giamaica 18
VE - Venezuela 18
AE - Emirati Arabi Uniti 17
UZ - Uzbekistan 17
CH - Svizzera 16
KE - Kenya 15
IL - Israele 13
MY - Malesia 13
EG - Egitto 12
RO - Romania 12
LT - Lituania 11
NG - Nigeria 11
PE - Perù 11
NP - Nepal 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
TW - Taiwan 10
DZ - Algeria 9
EU - Europa 9
JO - Giordania 9
KZ - Kazakistan 8
TH - Thailandia 8
BG - Bulgaria 7
GT - Guatemala 7
IR - Iran 7
NZ - Nuova Zelanda 7
OM - Oman 7
PT - Portogallo 7
AL - Albania 6
BB - Barbados 6
HN - Honduras 6
DK - Danimarca 5
ET - Etiopia 5
UY - Uruguay 5
AO - Angola 4
CM - Camerun 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GR - Grecia 4
KG - Kirghizistan 4
SK - Slovacchia (Repubblica Slovacca) 4
UG - Uganda 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
CI - Costa d'Avorio 3
GE - Georgia 3
KH - Cambogia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
MN - Mongolia 3
PS - Palestinian Territory 3
QA - Qatar 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
Totale 59.340
Salva come PNG Salva come JPEG
Città #
Woodbridge 11.094
Wilmington 10.917
Houston 8.878
Singapore 1.946
Fairfield 1.443
Ashburn 1.006
San Jose 942
Ann Arbor 913
Chandler 840
Hong Kong 649
Seattle 586
Beijing 524
Cambridge 460
Rome 429
Jacksonville 421
Dublin 398
Council Bluffs 375
New York 349
Kraków 324
Santa Clara 309
Medford 283
Dearborn 275
Helsinki 248
Los Angeles 245
The Dalles 226
Tokyo 190
Ho Chi Minh City 186
Milan 146
Hanoi 144
Lawrence 135
Buffalo 132
Moscow 109
Munich 109
Dallas 101
San Diego 99
São Paulo 96
Menlo Park 85
Nuremberg 80
Lauterbourg 77
Orem 69
Mülheim 65
Chicago 61
Zhengzhou 60
London 59
San Francisco 59
Brussels 50
Warsaw 48
Phoenix 47
Jakarta 46
Creede 44
Brooklyn 43
Montreal 41
Chennai 40
Denver 39
Boardman 37
Stockholm 37
Palo Alto 36
Redondo Beach 34
Toronto 34
Frankfurt am Main 33
Sydney 33
Naples 32
Poplar 32
Engelhard 31
Melbourne 31
Atlanta 30
North Bergen 30
La Veta 29
Amsterdam 28
Dong Ket 28
Johannesburg 27
Rio de Janeiro 27
Brno 25
University Park 25
Guangzhou 24
Haiphong 24
Mexico City 24
Redwood City 24
Cedarhurst 23
Vienna 23
Canberra 22
Columbus 22
Falls Church 22
Verona 22
Washington 22
Bari 21
Boston 21
Nanjing 21
Lappeenranta 20
Olomouc 20
Shanghai 20
Madrid 19
Colorado Springs 18
Da Nang 18
Curitiba 17
Manchester 17
Baghdad 16
Biên Hòa 16
Hefei 16
Mumbai 16
Totale 47.687
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 577
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 569
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 552
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 534
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 533
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 530
Therapeutic strategies towards HIV-1 infection in macrophages 519
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 511
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 508
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence 499
Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008 494
Understanding HIV compartments and reservoirs 494
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 493
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 489
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies 486
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 486
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 483
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 481
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 481
HIV-1-associated dementia during HAART therapy 480
Novel drug resistance mutations in HIV: Recognition and clinical relevance 477
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 476
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 476
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 475
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 474
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 471
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 470
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 467
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 467
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 467
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 462
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 462
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 461
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 459
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 458
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 452
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 448
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 448
Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme 447
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 446
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 444
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
Complete hbv prophylaxis withdrawal in HBsAg-positive liver transplant recipients after long-term minimal immunosuppression 444
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 443
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 443
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 441
Dynamics of NRTI resistance mutations during therapy interruption 440
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 439
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 439
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 439
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 437
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 436
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 435
Highlights on HIV eradication in 2013 435
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 432
Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage 432
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 430
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 430
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 428
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 427
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 427
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 427
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 422
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 422
Combined analysis of the prevalence of drug-resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe (CAPRE) 419
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 418
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 416
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 416
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 416
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 415
The role of HIV infection in neurologic injury 415
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 414
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 412
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 410
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B 409
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors 408
Temporal change in the use of genotypic resistance testing over the years 1999--2003 408
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 407
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 407
Does residual virus replication during successful HAART lead to HIV-1 genetic evolution? 405
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 403
Impact of pre-therapy viral load on virological response to modern first-line HAART 401
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 401
The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype 401
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 400
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 398
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 394
Selected Amino Acid Mutations in HIV-1 B Subtype gp41 are Associated with Specific gp120v3 Signatures in the Regulation of Co-Receptor Usage 392
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 389
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 382
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 380
Papillomavirus and cervical cancer: Epidemiology, genetics and prevention [Il papillomavirus umano e il cancro della cervice uterina: Epidemiologia, basi genetiche e prevenzione] 379
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 376
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 366
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 366
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. 364
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 362
Totale 44.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.877 114 141 118 97 80 163 86 78 365 145 74 416
2022/20232.309 250 196 145 267 192 465 162 225 182 33 155 37
2023/20241.272 223 35 113 61 123 198 62 24 77 142 25 189
2024/20255.914 175 1.071 499 344 221 396 563 259 612 328 746 700
2025/202610.130 882 417 921 910 941 448 1.259 1.245 1.186 853 566 502
2026/202794 94 0 0 0 0 0 0 0 0 0 0 0
Totale 60.258